China Orient Asset Management (International) Holding
VC Fund
Central, Hong Kong
China Orient Asset Management (International) Holding is a VC fund in Central focused on Health Care and Pharmaceutical. Headquartered in Hong Kong, China Orient Asset Management (International) Holding Limited (COAMCI), a wholly-owned subsidiary of China Orient Asset Management Co., Ltd. (COAMC), which founded in 2002 and subsequently restructured and renamed in June 2011.COAMCI is one of the Group’s primary overseas platform focusing on investment, assetmanagement etc, as a bridge between domestic resources and overseas markets, delivering a specialized, diversified and comprehensive range of financial services solution. Fully utilizing the company’s multi-market and multi-currency capabilities to its advantage. With the deep understanding of the Chinese market and the benefit of investment acumen in global markets, COAMCI has kept steady growth in asset value.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries China Orient Asset Management (International) Holding invests in
Stages China Orient Asset Management (International) Holding invests in
Countries China Orient Asset Management (International) Holding invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Quan Wang
|
|||
Ziqiang Wang
|
|||
Investment Focus
Industry
- Health Care 2 (33%)
- Pharmaceutical 2 (33%)
- Travel 1 (17%)
- Aerospace 1 (17%)
- Biopharma 1 (17%)
Stage
- Series C 2 (33%)
- Series D 1 (17%)
- Funding Round 1 (17%)
- Private Equity 1 (17%)
- Post-IPO Equity 1 (17%)
Country
- China 5 (83%)
- Canada 1 (17%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Chloe Zhang
COAMCI Department Head
|
COAMCI Department Head | Total investments: 0 | Find email | |
|
Quan Wang
CEO
|
CEO | Total investments: 0 | Find email | |
|
Ziqiang Wang
CFO
|
CFO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Tianbing Technology
|
Tianbing Technology is an advanced aerospace propulsion system supplier and aerospace vehicle provider. Tianbing Technology independently develops the next-generation ambient temperature green HCP liquid propellant and minimalist aerospace propulsion system. As an upgraded product of traditional chemical propulsion system, it can meetcost-effective aerospace. Advance system supporting needs. The next-generation green HCP aerospace propulsion system, first tested by Tianbing Technology, can be used in the small-vehicle main power and launch vehicle upper-level propulsion system. | $350.7M / Series D / Oct 09, 2025 | |
Shanghai Wai Gaoqiao Free Trade Zone Development
|
Shanghai Wai Gaoqiao Free Trade Zone Development is a publicly traded firm that offers the community a multipurpose free trade zone. They support the development and construction of urban living areas, the promotion and stabilization of investments, the cultivation of industries, and operation services. Additionally, they engage in industrialproduction, logistical services, and the leasing and distribution of real estate. | $339.2M / Post-IPO Equity / Apr 17, 2025 | |
ChangXin Memory Technologies
|
ChangXin Memory Technologies specializes in manufacturing dynamic random-access memory (DRAM) semiconductor products. | $1.2B / Series C / Feb 17, 2022 | |
Suzhou Kintor Pharmaceuticals
|
Kintor founded in Suzhou in 2009, focusing on prostate cancer, breast cancer and liver cancer which account for more than 50% of the global cancer population and lack of effective treatment method. They have a product pipeline built on proprietary R&D and licensing arrangement, aiming to provide the best treatment plans for huge unmet patientneeds. They focus on developing a full R&D and commercialization platform for “best-in-class” and “first-in-class” novel drugs. | $44M / Series C / Jan 12, 2018 | |
Yixin Capital
|
The firm aims to develop a consumer-centric automotive transaction platform which connects consumers with a partner network that includes automakers, auto dealers, financing and insurance partners, as well as aftermarket service providers. | $567M / Private Equity / May 12, 2017 | |
Angiotech Pharmaceuticals
|
Angiotech is a Vancouver, British Columbia pharmaceutical company. Its products enhance the performance of medical devices and biomaterials through the use of pharmacotherapeutics. Angiotech is a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarilyfor local diseases or for complications associated with medical device implants, surgical interventions and acute injury. | Mar 21, 2017 |
Co-Investors
Tencent
2 deals together
Alibaba Group
1 deal together
Bank of China Financial Assets Investment
1 deal together
Bitauto Holdings
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does China Orient Asset Management (International) Holding invest in?
China Orient Asset Management (International) Holding invests primarily in Health Care, Pharmaceutical and Travel startups, most often at Series C and Series D stage. Most of the 6 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact China Orient Asset Management (International) Holding?
Public channels for China Orient Asset Management (International) Holding include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at China Orient Asset Management (International) Holding?
The team at China Orient Asset Management (International) Holding includes Chloe Zhang (COAMCI Department Head), Quan Wang (CEO) and Ziqiang Wang (CFO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
